scispace - formally typeset
Y

Yves Pommier

Researcher at National Institutes of Health

Publications -  847
Citations -  65543

Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.

Papers
More filters
Journal Article

Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.

François Goldwasser, +4 more
- 15 May 1995 - 
TL;DR: An overall log-linear correlation was observed between CPT-induced top1-cleavable complexes and growth inhibition, indicating the importance of cleavable complex formation rather than top1 levels for cell killing in this panel of cell lines.
Journal ArticleDOI

Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison

Glenda Kohlhagen, +4 more
- 01 Jul 1998 - 
TL;DR: Results demonstrate that NSC 314622 is a novel top1-targeted drug with a unique chemical structure that is comparable to the topoisomerase I (top1) inhibitors camptothecin (CPT) and saintopin in the National Cancer Institute In Vitro Anticancer Drug Discovery Screen using the COMPARE analysis.
Journal ArticleDOI

Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Repairs DNA Damage Induced by Topoisomerases I and II and Base Alkylation in Vertebrate Cells

Junko Murai, +5 more
- 13 Apr 2012 - 
TL;DR: A broad involvement of Tdp1 in DNA repair is revealed and the role of human TDP1 in the repair of Top2-induced DNA damage is clarified.
Journal ArticleDOI

Targeting Topoisomerase I in the Era of Precision Medicine

Anish Thomas, +1 more
- 15 Nov 2019 - 
TL;DR: New therapeutic strategies based on novel TOP1 inhibitor chemical scaffolds including the indenoisoquinolines LMP400, LMP776, and LMP744 are introduced, and on tumor-targeted delivery TOP1 inhibitors using liposome, PEGylation, and antibody–drug conjugates are addressed.
Journal ArticleDOI

ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases

Laurent Candeil, +13 more
- 10 May 2004 - 
TL;DR: It is shown, for the first time in clinical samples, that the ABCG2 mRNA content in hepatic metastases is higher after an irinotecan‐based chemotherapy than in irinodiazepine‐naive metastases, which supports the potential involvement of ABCG1 in the development of irinOTecan resistance in vivo.